Strong quarter masked by guidance caution and macro headwinds

Delivered ₹4384.1 Cr YoY +17.5% reported; 8.3% CC implies ~9.2% FX tailwind

Delivered OPM 18.1%, which is above the stated guidance band

Pipeline composition and TCV mix disclosed; no contradicting data in results

Net new TCV stated; TCV-to-revenue correlation fell to 0.74 from 0.9+, indicating faster short-cycle conversion

Forward guidance; Q1 itself was 2.1% QoQ, so Q2 claim is unverified but consistent with pipeline/ramp narrative

Q1 delivered 8.3% CC (at bottom of range); prior FY26 guidance was 'more than double industry average'—this is a step-down

FY26 guidance was 'more than double industry average' with Q4 'strongest sequential.' FY27 now 'high single-digit to low double-digit' CC growth. Q1 delivered 8.3% CC (bottom of range), signaling caution.

Shift from model adoption to Enterprise Agency: measurable ROI, governance, outcome-based pricing. Tria 7-week closure cycle, 70% of pipeline AI-led (up from 12% prior).

Maintained 14.75–15.75% EBIT band; Q1 beat at 18.1%, but mgmt flagged deliberate investment phase (ramp costs, utilization drop, TAP drag 0.35%). Expect normalization as deals scale.

FY26 +35% YoY, Q1 down 3.1% QoQ due to project milestone completions and transformation program cost ramp. Expected to normalize in 2 quarters.

Macro is complex. We see macro uncertainty but client conversations are strong. Insurance slowdown was project milestone-driven, not client loss. Logistics headwinds are geopolitical, not demand. Traditional discretionary spend model is changing—new budget pools open when AI shows 1% revenue uplift or better forecasting.

Not a trade-off for market share grab via pricing. Ramp costs were deliberate investment ahead of Q2 growth, and TAP acquisition is one-time drag. As platform adoption expands and attach rates show up, we expect gross margin expansion; how much to reinvest is our call. Outcome-based pricing also gives operating leverage beyond traditional capacity pricing.

Red Oak baked into FY27 guidance but consummation ~end-Aug, so partial Q2 benefit. Growth guidance is broad-based (pipeline, TCV, utilization investment made in Q1). Organic business momentum is strong independent of Red Oak.

TAP earn-out: 0.35% (multiyear P&L drag, not one-time). Utilization drop: deliberate ramp-ahead investment, should reverse as deals convert. Expect normalization as investments pay off over the year. Hedge losses trending down (₹50 Cr improvement March–June in OCI).

Frontier models will commoditize fast. Real opportunity is helping clients build model-agnostic stacks (SLMs, governance, open-weight models) that survive model obsolescence. That's the bet we're making with Tria—it's the stack, not the model.

OCI (cumulative hedge losses) down ₹50 Cr March–June; expect trend down if rupee stays ~95. Will take a couple quarters to show in operating margin. Hedge losses will improve but not go away fully.

Q1 OCF was depressed by Q4 debtor collection delays and seasonal FY26 variable pay (both expected). Other current liabilities also paid down (~$14M contract acquisition costs). These are known; 80% OCF/PAT target stands and is realistic for full year.

Transformation program required team ramp-up. Normalization expected within 2 quarters. These are conscious investments yielding 35% FY26 growth and future expansion. Structural margins will return once delivery phase completes.

Short-burst, early deployment deals convert quickly (within 1–2 quarters), so correlation falls. This is positive—proof-of-value deals that then lead to scale waves (foundation 12–16 weeks, then 6–7 deployment waves on top). Velocity is accelerating, but timing spreads.

Expected end-Aug to early-Sep. Contract assignment and employee takeover in progress. Will complete in that timeframe.

Upfront costs are expensed (not capitalized as M&A). After expensing, deal is structured to be profitable in line with company average. May vary quarter-to-quarter, but contracted margin will play out after ramp phase. We don't buy low-margin businesses to transform; consolidation deals give us leverage on price and longevity.

Traditional deal renewal cycles have fiercer pricing pressure. We're not competing on price; we compete on AI-led transformation (outcome-based models). If you stand still, pricing pressure intensifies. We're forward-leaning on deployment and avoiding productivity forecasting traps (60–70% claims unproven). Outcome-based pricing model makes price competition irrelevant for clients.

Large deals won require 12–18 month upfront capital investment; expect normalization in FY28. Once deals mature, they generate incremental cash (recovery of upfront), which funds new deals. This is a transition into large deals/managed services/outcome-based; it will normalize from FY28.

Stepped down from prior 'more than double industry average'; Q1 delivered 8.3% CC (at bottom of range). Macro uncertainty acknowledged; pipeline strong but deal velocity timing unpredictable (TCV-to-revenue correlation shifted to 0.74).

Q1 beat at 18.1%, but management signals normalization as investments (ramp costs, TAP earn-out 0.35%) pay off and utilization recovers. Expect margin recovery in H2 if Q2 growth materializes and platform adoption scales.

Large deals require 12–18 month upfront investment before cash recovery. CFO flagged $14M Q1 for contract acquisition costs; normalization expected FY28.

Tria is 7 weeks post-launch with early wins showing promise (70% of pipeline AI-led, 63% TCV wins AI-led), but scale and profitability at enterprise level unproven. Deployment-ready stack claim needs multi-client validation.

CEO acknowledged macro complexity (interest rates reversing, Fed uncertainty, geopolitics). Clients showing caution on program commitments despite strong pipeline. Traditional discretionary spend model at risk if economic shocks hit.

Q1 EBIT margin beat at 18.1% vs guidance 14.75–15.75%, but management flagged utilization drop (deliberate ramp), ramp costs, and TAP earn-out (0.35%) as headwinds. If Q2 'best sequential growth in 3 years' claim fails, investment thesis breaks and margins compress below guidance band.

TCV-to-revenue correlation fell from 0.9+ to 0.74 due to short-burst/early deployment deals converting in 1–2 quarters. While this signals faster proof-of-value, it complicates revenue predictability and increases near-term timing risk.

CEO noted fiercer pricing pressure on traditional deal renewal cycles. Mphasis is steering away from price competition toward outcome-based models, but not all peers are following; risk of price wars on legacy services.